<DOC>
	<DOCNO>NCT00409175</DOCNO>
	<brief_summary>This study examine whether Fx-1006A effective halting progression Familial Amyloid Polyneuropathy ( FAP ) . Deposition TTR amyloid associate variety human disease . Deposition amyloid fibril variant TTR ( primarily V30M ) peripheral nerve tissue produce condition call FAP . The prevention formation amyloid stabilization TTR native state constitute effective therapy amyloid disease . Therapeutic intervention TTR stabilizer drug , Fx-1006A , hypothesize stop progression disease FAP patient . FAP uniformly fatal disease Fx-1006A intend halt relentless neurological deterioration FAP patient experience . This Phase 2/3 study enroll early mid-stage FAP patient order interrupt stabilize disease point time progression motor autonomic dysfunction maximally effect . Male female patient FAP document V30M TTR mutation receive Fx-1006A placebo daily period eighteen ( 18 ) month .</brief_summary>
	<brief_title>Safety Efficacy Study Fx-1006A Patients With Familial Amyloidosis</brief_title>
	<detailed_description>Deposition TTR amyloid associate variety human disease . Deposition amyloid fibril variant TTR ( primarily V30M ) peripheral nerve tissue produce condition call FAP . The prevention formation amyloid stabilization TTR native state constitute effective therapy amyloid disease . Therapeutic intervention TTR stabilizer drug , Fx-1006A , hypothesize stop progression disease FAP patient . FAP uniformly fatal disease Fx-1006A intend halt relentless neurological deterioration FAP patient experience . This Phase 2/3 study enroll early mid-stage FAP patient order interrupt stabilize disease point time progression motor autonomic dysfunction maximally effect . Male female patient FAP document V30M TTR mutation receive Fx-1006A placebo daily period eighteen ( 18 ) month .</detailed_description>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Amyloid Neuropathies</mesh_term>
	<mesh_term>Amyloid Neuropathies , Familial</mesh_term>
	<criteria>1 . Amyloid document biopsy . 2 . Documented V30M TTR mutation . 3 . Peripheral and/or autonomic neuropathy Karnofsky Performance Status ≥50 . 4 . Patient 1875 year old . 5 . If female , patient postmenopausal , surgically sterilize , willing use acceptable method birth control . If male female partner childbearing potential , willing use acceptable method birth control duration study . For female male , birth control must use least 3 month last dose study medication . 6 . Patient , opinion investigator , willing able comply study medication regimen study requirement . 1 . Chronic use nonsteroidal antiinflammatory drug ( NSAIDs ) . 2 . Primary amyloidosis . 3 . If female , patient pregnant breast feeding . 4 . Prior liver transplantation . 5 . No recordable sensory threshold vibration perception foot , measure CASE IV . 6 . Positive result hepatitis B surface antigen ( HBsAg ) , antihepatitis C virus ( HCV ) , and/or human immunodeficiency virus ( HIV ) . 7 . Renal insufficiency liver function test abnormality . 8 . New York Heart Association ( NYHA ) Functional Classification ≥III . 9 . Other cause sensorimotor neuropathy ( B12 deficiency , Diabetes Mellitus , HIV treat retroviral medication , thyroid disorder , alcohol abuse , chronic inflammatory disease ) . 10 . Comorbidity anticipated limit survival le 18 month . 11 . Patient receive investigational drug/device and/or participate another clinical investigational study within 60 day Baseline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>FAP</keyword>
	<keyword>Fx-1006A</keyword>
	<keyword>transthyretin</keyword>
	<keyword>TTR</keyword>
	<keyword>amyloid</keyword>
	<keyword>polyneuropathy</keyword>
	<keyword>V30M</keyword>
	<keyword>familial</keyword>
	<keyword>hereditary</keyword>
	<keyword>amyloidosis</keyword>
	<keyword>FoldRx</keyword>
</DOC>